References

  1. Van Lier, D. & Pickkers, P. Circulating biomarkers to assess cardiovascular function in critically ill. Curr. Opin. Crit. Care 27, 261–268 (2021).
  2. Van Diepen, S. et al. Contemporary Management of Cardiogenic Shock: A Scientific Statement from the American Heart Association. Circulation vol. 136 (2017).
  3. Arrigo, M. et al. Current and future trial design in refractory cardiogenic shock. Eur. J. Heart Fail. 25, 609–615 (2023).
  4. Kimmoun, A. et al. Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop. The Lancet Respiratory Medicine, Volume 13, Issue 9, 833 – 842 (2025)
  5. Malik, A. O. et al. Hospital-Level Variability in Use of Intracoronary Imaging for Percutaneous Coronary Intervention in the United States. J. Soc. Cardiovasc. Angiogr. Interv. 2, 100973 (2023).
  6. Picod, A. et al. Targeting high circulating dipeptidyl peptidase 3 in circulatory failure. Crit Care 29, 340 (2025). https://doi.org/10.1186/s13054-025-05545-x
  7. Mebazaa, A. et al. Management of cardiogenic shock complicating myocardial infarction. Intensive Care Med. 44, 760–773 (2018).
  8. Berg, D. D. et al. Epidemiology of Shock in Contemporary Cardiac Intensive Care Units: Data from the Critical Care Cardiology Trials Network Registry. Circ. Cardiovasc. Qual. Outcomes 12, 1–10 (2019).
  9. Møller, J. E. et al. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N. Engl. J. Med. 390, 1382–1393 (2024).
  10. Deniau, B. et al. Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. Eur. J. Heart Fail. 1–10 (2019) doi:10.1002/ejhf.1601
  11. Takagi, K. et al. Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial. Eur. J. Heart Fail. 1–8 (2019) doi:10.1002/ejhf.1600.
  12. Blet, Al. et al. Critical Care Medicine Monitoring Circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. 3, 1–10 (2021).
  13. Deniau, B. et al. High plasma dipeptidyl peptidase 3 levels are associated with mortality and organ failure in shock: results from the international, prospective and observational FROG-ICU cohort. Br. J. Anaesth. 128, e54–e57 (2022).
  14. Wenzl, F. A. et al. Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes. Eur. Heart J. 44, 3859–3871 (2023).
  15. Dépret, F. et al. Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients. 1–8 (2020) doi:10.1186/s13054-020-02888-5.
  16. Picod, A. et al. Circulating Dipeptidyl Peptidase 3 Modulates Systemic and Renal Hemodynamics Through Cleavage of Angiotensin Peptides. Hypertension 81, 927–935 (2024).
  17. Deniau, B. et al. Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: A proof of concept study. PLoS One 15, 1–12 (2020).
  18. Garcia, B. et al. Inhibition of circulating dipeptidyl-peptidase 3 by procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury. Intensive Care Med. Exp. 12, 53 (2024).
  19. Jarczak, D. et al. Targeting dipeptidyl peptidase 3 (DPP3) in extreme-critically ill patients with refractory shock: First-in-human report on the safety and efficacy of an anti-DPP3 antibody. https://doi.org/10.1002/ejhf.3718 (2025).